Side-by-side · Research reference
PancragenvsVilon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED23/39 cited
BAnimal-StrongHUMAN-REVIEWED13/49 cited
Vilon
Khavinson Bioregulator · Dipeptide
Literature lacks standardised clinical route
01Mechanism of Action
Parameter
Pancragen
Vilon
Primary target
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Immune cell differentiation pathways, chromatin modification
Pathway
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)
Downstream effect
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011Khavinson 2002Lezhava 2023
Feedback intact?
Yes — preserves physiological glucose-insulin response
Unknown — no HPA/HPG axis data
Origin
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997
Antibody development
—
—
02Dosage Protocols
Parameter
Pancragen
Vilon
Primate dose (rhesus macaque)
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
—
Effective concentration (in vitro)
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
—
Route
IntramuscularGoncharova 2015
Likely SQ or oral (Khavinson school uses both); no published ROA validation
Frequency
Once daily for 10 daysGoncharova 2014
Unknown — literature does not specify chronic administration protocols
Evidence basis
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Mouse / in vitro only
Diabetes model
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
—
Standard dose
—
No clinical standard — literature lacks human dosing
Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.
Animal model dose
—
In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)
Not translatable to human mg/kg without pharmacokinetic data.
Duration
—
Not characterised in humans
Half-life
—
Not published — dipeptides typically <10 min plasma t½
04Side Effects & Safety
Parameter
Pancragen
Vilon
Reported adverse events
None documented in primate studies
—
Human safety data
No published human trials; clinical use limited to Russian gerontology protocols
Absent from PubMed-indexed literature
Theoretical risk
—
Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)
Antibody formation
—
Not reported; dipeptides generally low immunogenicity
Animal models
—
No adverse effects noted in mouse thymocyte or pineal lymphoid cultures
Absolute Contraindications
Pancragen
—Vilon
- ·Active autoimmune disease (theoretical — no clinical data)
Relative Contraindications
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
Vilon
- ·Pregnancy / lactation (no safety data)
- ·Acute infection with cytokine storm risk (immune modulation unknown)
05Administration Protocol
Parameter
Pancragen
Vilon
1. Reconstitution
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.
2. Route
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.
3. Timing
No specific timing constraints documented. Administered once daily in primate protocols.
Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.
4. Cycle structure
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
Likely lyophilised powder, refrigerated. Reconstitution protocols not published.
06Stack Synergy
Pancragen
— no documented stacks
Vilon
+ Epitalon
ModerateBoth are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.
- Vilon
- Empirical — no standard
- Epitalon
- Empirical — often 10 mg cycles
- Frequency
- Sequential or concurrent (literature ambiguous)
- Primary benefit
- Multi-system aging modulation (immune + pineal/circadian)
+ Thymalin
WeakThymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.
- Vilon
- No standard
- Thymalin
- 10–100 mg IM (polypeptide complex)
- Primary benefit
- Redundant — both target T-cell differentiation